To get the approvals, King promised verbally not to promote AtroPen until the FDA's neuropharmacological drug products division had a chance to assess the policyimplications of distributing counter-terror drugs and look at and comment on the AtroPen marketing materials.
The reports were published in searchable form on several news websites, including WSJ.com, and allowed teachers and parents to consider the real-life implications of policy questions that until now had only been hypothetical.